奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告

Group 1: Share Buyback Announcement - The company has approved a share buyback plan with a total fund of no less than RMB 60 million and no more than RMB 120 million, with a maximum buyback price of RMB 25.00 per share, to be completed within 12 months [2] - As of October 31, 2025, the company has repurchased 2,124,938 shares, accounting for 0.52% of the total share capital, with a total expenditure of RMB 44,006,599.68 [4] - The maximum buyback price has been adjusted to RMB 24.71 per share following the annual profit distribution plan [3] Group 2: Shareholder Reduction Plan - Major shareholders hold a total of 167,919,800 shares, representing 41.34% of the company's total shares, with specific holdings detailed for each entity [9] - The shareholder Tian Tai Bo En plans to reduce its holdings by up to 1,000,000 shares within three months after the announcement, which is 0.25% of the total share capital [10] - The reduction is aimed at meeting the financial needs of some partners and has been planned in accordance with previous commitments made during the IPO [12][14]